Mostrar el registro sencillo del ítem
dc.contributor.author | Varani, Andrés P. |
dc.contributor.author | Aso Pérez, Ester |
dc.contributor.author | Machado Moutinho, Lirane |
dc.contributor.author | Maldonado, Rafael, 1961- |
dc.contributor.author | Balerio, Graciela N. |
dc.date.accessioned | 2016-01-22T07:54:58Z |
dc.date.available | 2016-01-22T07:54:58Z |
dc.date.issued | 2014 |
dc.identifier.citation | Varani AP, Aso E, Moutinho LM, Maldonado R, Balerio GN. Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations. Psychopharmacology (Berl). 2014 Aug;231(15): 3031-40. DOI: 10.1007/s00213-014-3469-6 |
dc.identifier.issn | 0033-3158 |
dc.identifier.uri | http://hdl.handle.net/10230/25635 |
dc.description.abstract | RATIONALE: Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. OBJECTIVES: The aim of the present study was to evaluate the possible role of GABAB receptor in responses induced by repeated nicotine administration in Swiss Webster mice. RESULTS: Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABAB receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. CONCLUSIONS: These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABAB receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation. |
dc.description.sponsorship | This work has been supported by grants from University of Buenos Aires (UBACyT B016 and UBACyT 2013-2016 Nº 20020120100244), CONICET (PIP 11420090100303), Spanish “Ministerio de Ciencia e Innovación” (#SAF2011-29864), “Instituto de Salud Carlos III” (RETICS: #RD06/0001/0001, #RD06/0001/1004), Plan Nacional sobre Drogas (PNSD#2009/026), the CatalanGovernment/n(SGR2009-00131), and the ICREA Foundation (ICREA Academia-2008). Andrés P. Varani is a doctoral fellow of the University of Buenos Aires (677/10). |
dc.format.mimetype | application/pdf |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartof | Psychopharmacology (Berl). 2014 Aug;231(15): 3031-40 |
dc.rights | © Springer (The original publication is available at www.springerlink.com) |
dc.subject.other | Àcid aminobutíric -- Farmacologia |
dc.subject.other | Nicotina |
dc.subject.other | Abús de substàncies |
dc.subject.other | Aminoàcids |
dc.title | Attenuation by baclofen of nicotine rewarding properties and nicotine withdrawal manifestations |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | http://dx.doi.org/10.1007/s00213-014-3469-6 |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/3PN/SAF2011-29864 |
dc.rights.accessRights | info:eu-repo/semantics/openAccess |
dc.type.version | info:eu-repo/semantics/acceptedVersion |